IMMUNOVANT, INC. Cash and Cash Equivalents, Period Increase (Decrease)
IMMUNOVANT, INC. (IMVT) reported Cash and Cash Equivalents, Period Increase (Decrease) of $1.29 million for the 9-month period ending 2019-09-30, per its 10-Q filed 2019-11-13.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-11-13
- IMMUNOVANT, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was -$301.50K.
- IMMUNOVANT, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $1.76M.
- IMMUNOVANT, INC. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$177.20K.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month |
|---|---|---|---|
| 2019-09-30 | -$301.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-13 | $1.46M derived: sum of 2 quarters · filed 2019-11-13 | $1.29M 10-Q · filed 2019-11-13 |
| 2019-06-30 | $1.76M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $1.59M 10-Q · filed 2019-08-12 | |
| 2019-03-31 | -$177.20K 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |